




# EV-Omics: Your Window to Powerful New Biomarkers

We are revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, better trials, better drugs and better outcomes. Our proprietary EV-Omics (EVO) platform enriches disease-derived extracellular vesicles (EVs). EV's are small, membrane-bound structures that are released from cells into the surrounding environment. We offer reliable, blood-based discovery and detection of protein and transcriptomic (RNA) biomarkers.

## SPARCIing Enriched Discovery


● Background ● Disease Markers

Selective Protein Affinity Reagent Chemistries (SPARCs™), our proprietary targeting technology enables the enhanced interrogation of disease-relevant information. Unlike current conventional methods, SPARCs enrich desired targets, and reduce background noise, further unlocking the full potential of EVs for liquid biopsies.



## EV-Omics (EVO) Discovery Platform


Our breakthrough EVO Platform employs SPARCs to enrich disease or tissue-associated EV subpopulations. Utilizing AI-enabled multiomic insights, EVO unravels the complexity of disease mechanisms. This unparalleled view provided by our multiomics approach can transform drug development and precision medicine.



## The FYR Difference, Igniting Your Success

The rich insights provided by our multiomic liquid biopsy approach can transform drug development from pre-clinical through clinical stages. With us as a partner, your clinical trial and drug development teams can more easily:

- Increase the effectiveness of clinical trial design and management
- Identify markers of disease with enhanced sensitivity
- Increase the understanding of disease mechanisms and treatment responses
- Provide longitudinal insights into treatment response/disease progression
- Detect early markers of disease
- Aid in go/no-go decisions in advance of clinical endpoint observations
- Identify novel drug targets



## Are You Ready to SPARC Innovation?

Our team can be your partner at every stage of the drug development process and help your company upgrade its biomarker discovery and detection capabilities. We're here to help at every step along the way.

**Scan the QR code below or contact us directly at [bd@fyrdiagnostics.com](mailto:bd@fyrdiagnostics.com) to learn more.**



[www.fyrdiagnostics.com](http://www.fyrdiagnostics.com)  
📺 @FYR Diagnostics  
✖ @FYR\_Dx